Building toward FDA drug approval, Peninsula biotech targets $605M stock offering

MyoKardia Inc., which earlier this week disclosed solid early data from a late-stage clinical trial of an experimental heart drug, plans to sell more stock on the good news to net $605 million. The Brisbane company said Thursday that BofA Securities Inc., J.P. Morgan Securities LLC and Credit Suisse Securities LLC will underwrite the sale of 5.25 million shares at $105 per share, and those investment banks will have a 30-day option to buy an additional 787,500 shares at $100.275 per share. Theā€¦

Click to view original post